Airway Inflammation News and Research

RSS

New target for control of early-stage asthma

New target for control of early-stage asthma

A new target for control of early-stage asthma has been identified by McGill University professor Qutayba Hamid, working as part of a team whose landmark study appears in the latest issue of the journal Science.

14 Jun 2004

Once-daily treatment with Alvesco (ciclesonide) in asthma patients has no effect on normal adrenal function

Once-daily treatment with Alvesco (ciclesonide) in asthma patients has no effect on normal adrenal function

New data presented at the American Thoracic Society’s 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.

24 May 2004

Experts call for better support and understanding of asthma

Experts call for better support and understanding of asthma

Leading experts in asthma have called for greater recognition and action amongst healthcare professionals and patients regarding the current status of asthma management across Europe.

26 Apr 2004

FDA approves Advair Diskus® for children with asthma

FDA approves Advair Diskus® for children with asthma

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) approved the use of Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.

22 Apr 2004

GlaxoSmithKline files asthma treatment drug for approval in Japan

GlaxoSmithKline files asthma treatment drug for approval in Japan

GlaxoSmithKline plc announced today that it has filed SeretideTM DiskusTM for approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of asthma in adults and children.

16 Apr 2004

Previous
1
...
13
14
15
16

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.